Sarepta Therapeutics, Inc. (SRPT)

Check out top investors' recommendation for SRPT
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
219.50
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Alethia Young Deutsche Bank Securities Buy   Jun 25, '19     231.00  Jun 25, '20  N/A 
Edward Tenthoff Piper Jaffray Buy   Jun 21, '19     208.00  Jun 21, '20  N/A 
Alethia Young Deutsche Bank Securities Buy   Mar 25, '19     231.00  Mar 25, '20  N/A 
Chad Messer Needham & Company Buy   Mar 25, '19     196.00  Mar 25, '20  N/A 
Matthew Harrison UBS Buy   Mar 04, '19     169.00  Mar 04, '20  N/A 
Brian Abrahams Wells Fargo Securities, Llc Buy   Feb 28, '19     192.00  Feb 28, '20  N/A 
Edward Nash Cowen And Company Buy   Feb 27, '19     176.00  Feb 27, '20  N/A 
Ritu Baral Canaccord Genuity Buy   Feb 27, '19     178.00  Feb 27, '20  N/A 
Christopher Marai Wedbush Securities Inc. Buy   Feb 12, '19     205.00  Feb 12, '20  N/A 
Alethia Young Deutsche Bank Securities Buy   Feb 07, '19     217.00  Feb 07, '20  N/A 
Tim Chiang CRT Capital Group Buy   Feb 05, '19     190.00  Feb 05, '20  N/A 
Edward Tenthoff Piper Jaffray Buy   Jan 30, '19     200.00  Jan 30, '20  N/A 
Salveen Richter Canaccord Genuity Buy   Jan 08, '19     191.00  Jan 08, '20  N/A 
Brian Skorney Brean Murray, Carret & Co. Buy   Jan 08, '19     202.00  Jan 08, '20  N/A 
Matthew Harrison UBS Buy   Jan 08, '19     161.00  Jan 08, '20  N/A 
Brian Abrahams Wells Fargo Securities, Llc Buy   Jan 07, '19       Jan 07, '20  N/A 
Alethia Young Deutsche Bank Securities Buy   Nov 26, '18     217.00  Nov 26, '19  N/A 
Matthew Harrison UBS Buy   Oct 04, '18     163.00  Oct 04, '19  N/A 
Edward Nash Cowen And Company Buy   Oct 04, '18     176.00  Oct 04, '19  N/A 
Brian Abrahams Wells Fargo Securities, Llc Buy   Sep 26, '18     200.00  Sep 26, '19  N/A 
< previous12345678